Program
tarlatamab
Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms · Prostatic Neoplasms, led by Amgen.
Drug pageAMG 757: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 1312 open or running | phase 3since Feb 7, 2023 | Oct 5, 2017 | Apr 24, 2027phase 1 · NCT06598306 |
Also a collaborator on its studies: AstraZeneca and BeOne Medicines.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 2 earlier studies, Oct 5, 2017 to Jan 7, 2021.
- Jun 9, 2020Named tarlatamabINNProposed as its International Nonproprietary Name in WHO's List 123
- Sep 17, 2021Phase 2 study in Small Cell Lung CarcinomaNCT05060016 · 222 enrolled · United States, Austria, Belgium and more
- Feb 7, 2023Phase 3 study in Small Cell Lung CarcinomaNCT05740566 · 509 enrolled · United States, Argentina, Australia and more
- Oct 31, 2023Phase 3 study in Small Cell Lung CarcinomaNCT06117774 · 404 enrolled · United States, Argentina, Australia and more
- Jan 8, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06211036 · 563 enrolled · United States, Argentina, Australia and more
- Jul 9, 2024Phase 2 study in NeoplasmsNCT06502977 · 32 enrolled · China
- Sep 13, 2024Phase 1 study in Small Cell Lung CarcinomaNCT06598306 · 220 planned · United States, Australia, Belgium and more
- Dec 17, 2024Phase 2 study in Small Cell Lung CarcinomaNCT06745323 · 252 enrolled · United States, Argentina, Australia and more
- Mar 21, 2025Phase 1 study in Small Cell Lung CarcinomaNCT06898957 · 29 enrolled · United States, Canada, China and more
- May 27, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07005128 · 350 enrolled · United States, Argentina, Australia and more
- Apr 9, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07531095 · 160 planned · United States, Australia, Belgium and more
- Aug 12, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07778316 · 400 planned · United States, Australia, China and more
- Oct 6, 2026Primary completion moved from 2029-05-10 to 2029-08-10Date moved laterphase 2 · +3 months · NCT06745323
- Nov 4, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 1 · +12 months · NCT03319940
- Nov 6, 2026Primary completion moved from 2027-07-05 to 2030-04-02Date moved laterphase 3 · +33 months · NCT06211036
Ahead
- Apr 24, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06598306
- Sep 24, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07778316
- Dec 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT05060016
- Dec 31, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT03319940
TargetBeta
“A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07778316Small Cell Lung Carcinoma · United States, Australia, China and more | 3 | Recruiting | Sep 24, 2027 | 400 |
| NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | May 21, 2028 | 160 |
| NCT07005128Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 4, 2029 | 350 |
| NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more | 1 | Active, not recruiting | Jun 23, 2031 | 29 |
| NCT06745323Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 10, 2029 | 252 |
| NCT06598306Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | Apr 24, 2027 | 220 |
| NCT06502977Neoplasms · China | 2 | Active, not recruiting | Mar 28, 2025 | 32 |
| NCT06211036Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 2, 2030 | 563 |
| NCT06117774Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 20, 2030 | 404 |
| NCT05740566Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 29, 2025 | 509 |
| NCT05060016Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 2 | Active, not recruiting | Dec 30, 2027 | 222 |
| NCT04702737Neuroendocrine Prostate Cancer · United States, Australia, Austria and more | 1 | Completed | Jul 22, 2024 | 41 |
| NCT03319940Small Cell Lung Carcinoma · United States, Australia, Austria and more | 1 | Active, not recruiting | Dec 31, 2027 | 269 |
How it is read
Names in the registry
- “Tarlatamab”, 13 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.